Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

Decapeptide-12 (Lumixyl): what the evidence says

Name: Decapeptide-12 (Lumixyl)
Published: 2026-10-27

At a glance

What it is: a 10-amino-acid peptide sold as Lumixyl for skin lightening. ^R1 In lab tests it blocked tyrosinase, the enzyme that makes skin pigment. ^R2 Its exact sequence could not be confirmed from a primary source. UNVERIFIED

What the evidence says: Human a 5-person split-face pilot RCT in melasma favored the peptide over placebo, and open-label studies of skin-care systems containing it reported fading of melasma. ^{R3, R4} Animal In the lab it blocked tyrosinase more strongly than hydroquinone, but no trial has compared the two in people. ^R2

Biggest risks: well tolerated in small studies, with no irritation reported. ^{R3, R4}

Rating


Human Human evidence	Very limited: pilot RCT (n = 5) and small open-label studies ^{R3, R4}
Animal Animal / lab evidence	Lab enzyme and cell studies ^R2
Regulatory	Cosmetic ingredient; not FDA-approved ^R5 · not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page ^{R6, R7, R8} · not named by WADA ^R9
Established human dose	No

Evidence verdict: Melasma and dark spots: Very limited (a 5-person pilot RCT plus small open-label studies, mostly of multi-step systems) · Compared with hydroquinone in people: No human data (no head-to-head trial found)

This page reports what studies used. It is not dosing advice.

Legend: HUMAN data · ANIMAL / LAB data · UNKNOWN · UNVERIFIED: not yet confirmed against a primary source

About the evidence: the only controlled study had 5 people; most other studies were open-label, used multi-step systems (cleanser, glycolic acid, sunscreen) and had no comparison group, so the peptide's own effect is unclear.

What is it?

Related pages: glutathione, ghk-cu, hexapeptide-11.

Does it work?

Animal Lab: blocked tyrosinase in a competitive way; in that study it was a stronger enzyme blocker than hydroquinone and cut melanin by 43% in pigment cells. ^R2
Human Melasma pilot (split-face RCT, n = 5, 16 weeks): all 5 improved on the treated side vs placebo. ^R3
Human Melasma, open-label (n = 33 Hispanic women, 16 weeks): with a four-step system containing the peptide, melasma severity scores fell 60%. ^R4
Human Other small reports: a 4-person case series and a 15-person open-label sun-damage study. ^{R10, R11}
Unknown Head-to-head vs hydroquinone in people: no trial found.

Is it safe?

Human No irritation or allergy reported in the pilot and open-label studies. ^{R3, R4}
Use sunscreen with any lightening product; stop if irritation develops.

Gray-market vials: extra risks

A gray-market vial has no quality control and no guarantee of identity, strength or sterility. We test retail vials blind under the Open Peptide Standard; see /tests/. A passing test covers one batch on one date and does not mean the compound is safe.

Is it legal?

US: sold as a cosmetic ingredient. Cosmetics do not need FDA approval before sale; products making drug-type claims can be regulated as drugs. ^R5 No Drugs@FDA application found (openFDA searched Oct 27, 2026).
Compounding: not on FDA's 503A or 503B bulk-substance category lists and not on FDA's compounding safety-risk page. ^{R6, R7, R8}
Sport: not named on WADA's 2026 Prohibited List. ^R9

Study details

These are amounts researchers used, not recommendations.

Study	People / model	Route	Amount used	Follow-up	Reported	Citation
Hantash 2009 (split-face RCT)	5 women with melasma	Topical	0.01% cream, twice daily	16 weeks	Improvement vs placebo side	PMID 19663110
Ramírez 2013 (open-label)	33 Hispanic women with melasma	Topical system	0.01% cream plus glycolic acid and sunscreen	16 weeks	Melasma score −60%	PMID 23839199

Full reference list (PubMed, CT.gov, FDA and WADA checked Oct 27, 2026)

^R1 PubChem CID 25087629, Decapeptide-12 (synonym Lumixyl), checked Oct 27, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/25087629
^R2 Abu Ubeid A, et al. J Invest Dermatol. 2009. PMID 19440221
^R3 Hantash BM, et al. J Drugs Dermatol. 2009. PMID 19663110
^R4 Ramírez SP, et al. J Drugs Dermatol. 2013. PMID 23839199
^R5 FDA. Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) Content current as of Sep 11, 2024. https://www.fda.gov/cosmetics/cosmetics-laws-regulations/it-cosmetic-drug-or-both-or-it-soap
^R6 FDA, 503A bulk drug substances categories list (updated May 14, 2026). https://www.fda.gov/media/94155/download
^R7 FDA, 503B bulk drug substances categories list (updated Mar 21, 2025). https://www.fda.gov/media/94164/download
^R8 FDA, Certain bulk drug substances for use in compounding that may present significant safety risks (content current Apr 22, 2026). https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
^R9 WADA. The 2026 Prohibited List, full list checked; compound not named. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
^R10 Hantash BM, et al. J Drugs Dermatol. 2012. PMID 22527440
^R11 Kassim AT, et al. J Cosmet Laser Ther. 2012. PMID 22401652

Disclaimer

This page is for education and harm reduction, not medical advice or a recommendation to use Decapeptide-12 (Lumixyl). This is a cosmetic ingredient, not an FDA-approved drug. Cosmetic products are not reviewed by FDA for effectiveness before sale. Report problems to FDA MedWatch (https://www.fda.gov/safety/medwatch).